IMMUNOVIA AB overview

Immunovia publishes the Annual Report for 2024 PR Newswire LUND, Sweden, April 2, 2025 LUND, Sweden , April 2, 2025 /PRNewswire/ -- Immunovia AB (publ) today announced that the Annual Report for 2024 has been published. The annual report can be downloaded in pdf format and is available on Immunovia's website. For more information, please contact: Jeff Borcherding CEO and President [email protected] Immunovia in brief Immunovia AB (IMMNOV: Nasdaq Stockholm), is a diagnostic company...

The exercise period for warrants series TO 3 begins today PR Newswire LUND, Sweden, April 1, 2025 LUND, Sweden , April 1, 2025 /PRNewswire/ -- Today, 1 April 2025 , the exercise period for warrants series TO 3 in Immunovia AB (publ) ("Immunovia" or the "Company") (the "Warrant Programme") begins. The exercise period runs until 15 April 2025 . Summarized terms for the warrants of series TO 3 Structure : One (1) warrant series TO 3 entitles the holder to subscribe for one (1) new share in the...

Immunovia announces determined exercise price for warrants series TO 3 PR Newswire LUND, Sweden, March 27, 2025 LUND, Sweden , March 27, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 3 (the "warrants") has been determined to SEK 0.24 . The exercise period for the warrants commences on 1 April 2025 and runs up to and including 15 April 2025 . The last day for trading in the warrants is 11 April 2025 ....

Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test PR Newswire LUND, Sweden, March 24, 2025 LUND, Sweden , March 24, 2025 /PRNewswire/ - - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic cancer test, strengthening the company's position as it prepares to launch the pancreatic cancer blood test...

Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study PR Newswire LUND, Sweden, March 21, 2025 LUND, Sweden , March 21, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm) , the pancreatic cancer diagnostics company, published positive results from the VERIFI clinical validation of its next-generation test for pancreatic cancer on March 19, 2025 . As a follow up, Immunovia will host a webcast on Monday, March 24 at 3 pm CET . Jeff Borcherding ,...

Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test PR Newswire LUND, Sweden, March 19, 2025 LUND, Sweden , March 19, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm) , the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second clinical validation study of its next-generation pancreatic cancer test. The study met its primary endpoint, with the test successfully detecting 77% of stage...

Immunovia's CLARITI study results selected for prestigious presentation at the world's largest gastroenterology conference PR Newswire LUND, Sweden, March 3, 2025 LUND, Sweden , March 3, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm) , the pancreatic cancer diagnostics company, today announces that the results of its CLARITI study have been selected for a distinguished plenary presentation at the upcoming Digestive Disease Week® (DDW) 2025 conference, taking place May 5, 2025 . The...

Immunovia Publishes Full Year Report for 2024 PR Newswire LUND, Sweden, Feb. 25, 2025 LUND, Sweden , Feb. 25, 2025 /PRNewswire/ -- October- December 2024 Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155). Net earnings were 3,1 MSEK (-49,0) as a result of unrealized exchange rate effects due to a higher dollar rate on the transactions to finance operations in Immunovia Inc. Operating losses were -30,1 MSEK (-23,4). Earnings per share before and after dilution...